Home • Industry Projects • Cilansetron - New Treatment for IBS • Image 1

Solvay SA, with headquarters in Brussels, Belgium, are developing Cilansetron, a 5-HT3 antagonist indicated for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS).

		Next»

---

Home | New On This Site | Products & Services | Company A-Z | Industry Projects | White Papers | Jobs & Careers | Press Releases | Events & Exhibitions | Newsletter | Organisations | About Us | Contact Us | Advertise With Us |